Revolutionary new bone cancer drug could save children’s lives

Published by  Communications

On 8th Mar 2023

A doctor examining an x-ray.
Getty images.

Researchers at the University of East Anglia have developed a new drug that works against all of the main types of primary bone cancer.


Cancer that starts in the bones, rather than cancer that has spread to the bones, predominantly affects children.

Current treatment is gruelling, with outdated chemotherapy cocktails and limb amputation.
Despite all of this, the five-year survival rate is poor at just 42 per cent – largely because of how rapidly bone cancer spreads to the lungs.

But a new study published today shows how a new drug called ‘CADD522’ blocks a gene associated with driving the cancer’s spread, in mice implanted with human bone cancer.

The breakthrough drug increases survival rates by 50 per cent without the need for surgery or chemotherapy. And unlike chemotherapy, it doesn’t cause toxic side effects like hair loss, tiredness and sickness.

Lead researcher Dr Darrell Green, from UEA’s Norwich Medical School, was inspired to study childhood bone cancer after his best friend died from the disease as a teenager. 


 

Now, the team has made what could be the most important drug discovery in the field for more than 45 years.

Dr Green said: “Primary bone cancer is a type of cancer that begins in the bones. It’s the third most common solid childhood cancer, after brain and kidney, with around 52,000 new cases every year worldwide.

“It can rapidly spread to other parts of the body, and this is the most problematic aspect of this type of cancer. Once the cancer has spread, it becomes very difficult to treat with curative intent.

“In high school, my best friend Ben Morley became ill with primary bone cancer. His illness inspired me to do something about it myself because during my studies I realised that this cancer has been all but left behind others in terms of research and treatment progress. So I studied and went through university and obtained my PhD to eventually work in primary bone cancer.

“I wanted to understand the underlying biology of cancer spread so that we can intervene at the clinical level and develop new treatments so that patients won’t have to go through the things my friend Ben went through.

“Ultimately, we want to save lives and reduce the amount of disability caused by surgery. And now we have developed a new drug that potentially promises to do just that.”

The team collected bone and tumour samples from 19 patients at the Royal Orthopaedic Hospital in Birmingham. However, this small number was more than enough to detect some obvious changes in the cancers.

The team used next generation sequencing to identify types of genetic regulators called small RNAs that were different during the course of bone cancer progression.

They also showed that a gene called RUNX2 is activated in primary bone cancer and that this gene is associated with driving the cancer’s spread.

They went on to develop a new drug called CADD522, a small molecule which blocks the RUNX2 protein from having an effect, and tested it in mice.

Dr Green said: “In preclinical trials, metastasis-free survival was increased by 50 per cent using the new CADD522 drug on its own, without chemotherapy or surgery. I’m optimistic that combined with other treatments such as surgery, this survival figure would be increased further.

“Importantly, because the RUNX2 gene is not usually required by normal cells, the drug doesn’t cause side effects like chemotherapy.

“This breakthrough is really important because bone cancer treatment hasn’t changed for more than 45 years.

“The new drug that we have developed is effective in all of the main bone cancer subtypes, and so far, our experiments show that it is not toxic to the rest of the body. This means that it would be a much kinder treatment for children with bone cancer, compared to the gruelling chemotherapy and life changing limb amputation that patients receive today.

“We hope it will save a lot of lives,” he added.

The drug is now undergoing formal toxicology assessment before the team assemble all of the data and approach the MHRA for approval to start a human clinical trial.

The research was led by UEA in collaboration with The University of Sheffield, Newcastle University, the Royal Orthopaedic Hospital, Birmingham, and the Norfolk and Norwich University Hospital.

This work has been funded by the Sir William Coxen Trust and Big C.

‘YBX1-interacting small RNAs and RUNX2 can be blocked in primary bone cancer using CADD522’ is published in the Journal of Bone Oncology.
 

Latest News

 
A nurse interacting with a patient.
21 Sep 2023

Nurses worldwide rely on intuition to triage patients

Nurses around the world use intuition to work out how sick a patient is before triaging for treatment – according to new research from the University of East...

Read more >
 
Francessca Turrell
18 Sep 2023

UEA nursing apprentice’s sky-high dive for Alzheimer's and Dementia awareness

On Sunday 24 September, University of East Anglia (UEA) nursing apprentice Francessca Turrell will be taking part in a charity skydive for Alzheimer’s Society, a...

Read more >
 
Logo Rewind's yellow book cover with black symbols
14 Sep 2023

New book to focus on Norwich’s medieval logos

‘Logo Rewind: Trademarks of Medieval Norwich’ is a new book from UEA Publishing Project, in collaboration with CreativeUEA and featuring the work of Darren...

Read more >
 
Ziggurats
13 Sep 2023

UEA students discover new room location following RAAC accommodation closures

Over 700 University of East Anglia (UEA) students have discovered where their new university homes will be located, following the closure of some accommodation...

Read more >
Are you searching for something?
 
Ziggurats
13 Sep 2023

UEA students discover new room location following RAAC accommodation closures

Over 700 University of East Anglia (UEA) students have discovered where their new university homes will be located, following the closure of some accommodation...

Read more >
 
(L-R) Chris Law MP, Dr Martin Scott, Renu Mehta
13 Sep 2023

New report from UEA Academic asks whether UK Aid Match has been used for ‘charity washing’, ahead of Westminster event

A new report from the University of East Anglia’s Dr Martin Scott into the Government’s UK Aid Match (UKAM) scheme has led to concerns of ‘charity washing’, with...

Read more >
 
Claudio Barchiesi with his bike and a United Kingdom flag
12 Sep 2023

Pedalling with purpose: UEA student’s fundraising cycle from Italy to England

A student at the University of East Anglia (UEA) has completed a charity cycling trip from his hometown in Italy to his grandparent’s house in Suffolk, to raise...

Read more >
 
Student accommodation buildings
11 Sep 2023

University of East Anglia accommodation closes following Government RAAC guidance

Read more >
 
A gloved hand holding a petri dish
11 Sep 2023

The University of East Anglia is set to re-join Horizon Europe

Read more >
 
A man speaking to a doctor.
08 Sep 2023

British sex lives revealed in new study

A new study published today shows the number of sexual partners we have changes as we age – and there are some surprising results. 

Read more >
 
Two women and a man stood together smiling at the camera
07 Sep 2023

UEA celebrates nurse’s six decades of local service with Honorary Fellowship award

With more than 60 years of nursing experience, Lesley Williams’ inspirational work across the region has been recognised with an Honorary Fellowship from the...

Read more >